BEIJING: Intense Chinese demand for initial public offerings on the country’s new stock board is sending valuations for new listings sky-high.
A biotech firm priced its shares at about 468 times reported earnings, according to a Shanghai exchange filing. That’s almost triple the most expensive of last week’s inaugural batch of debuts.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
